ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared with ibrutinib. ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared.

Slides:

Advertisements

Similar presentations

B-cell precursors in the spleen of Eμ-Myc mice are reduced by mTORC1 inhibition. B-cell precursors in the spleen of Eμ-Myc mice are reduced by mTORC1 inhibition.

Advertisements

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy Che-Hsin Lee, Chao-Liang Wu, Yun-Sheng.

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia by Zachary A. Hing, Rose Mantel,

Fig. 8. In vivo suppression of MM by CMLD

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

Therapeutic effects of TIP60 allosteric modification in DSS-induced colitis. Therapeutic effects of TIP60 allosteric modification in DSS-induced colitis.

VAY-736 combines effectively with ibrutinib in vivo.

Indomethacin worsens the effects of C. difficile infection in mice.

In vivo validation of effects of combination therapies on subpopulation composition. In vivo validation of effects of combination therapies on subpopulation.

CXCR5 expression accelerates Eμ-Tcl1 leukemogenesis and is indispensable for tumor cell recruitment to lymphoid B-cell follicles. CXCR5 expression accelerates.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts Therapeutic activity of gal‐encapsulated cytotoxic drugs on tumor xenografts.

AN12855 is efficacious in acute and chronic murine models of TB infection. AN12855 is efficacious in acute and chronic murine models of TB infection. (A,

Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.

Nrf2−/− mice suffered greater renal damage by STZ compared with Nrf2+/+ mice. Nrf2−/− mice suffered greater renal damage by STZ compared with Nrf2+/+ mice.

Anti-hOX40L treatment prevents aGVHD development in NOG mice transplanted with human PBMCs. NOG mice received human PBMCs (1 × 107) via tail vein. animals.

GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. Beginning.

A: Chemical structure of pterosin A

Prime and boosts with PBK001 vaccine provided 100% protection with low bacterial burden in organs. Prime and boosts with PBK001 vaccine provided 100% protection.

Effects of rhein on FBG (A) and glucose intolerance (B) in db/db mice.

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 has antileukemia activity in an in vivo primary AML xenograft.

Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.

Tumor metastasis is mediated by neutrophils.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

mTORC1 is required for malignant transformation in the Eμ-Myc model.

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but not OVA Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but.

EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,

Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated.

PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

Primary B16F10 tumor inhibits experimental metastasis formation in the lung. Primary B16F10 tumor inhibits experimental metastasis formation in the lung.

Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.

IDO deficiency delays the development of pulmonary metastases.

5FU-induced specific activation of CD8+ T cells.

Fig. 4 Dox-CBD-SA treatment shows reduced toxicity.

Antitumor effects of celastrol in vitro and in vivo.

Irradiated whole-cell vaccination with MOC1, but not MOC2, induces immunologic memory. Irradiated whole-cell vaccination with MOC1, but not MOC2, induces.

Efficacy of DC therapy is synergistically enhanced by combination therapy with TAM depletion in mesothelioma mouse models. Efficacy of DC therapy is synergistically.

A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.

Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.

ESKM treatment does not affect leukocyte or HSC counts in HLA-A

The responses of H292 and A549 lung cancer xenografts to hypofractionated radiation were enhanced by the ketogenic diet. The responses of H292 and A549.

Crebbp deficiency accelerates B-cell lymphoma development in mice.

PLX51107 demonstrates in vivo antitumor effects in a preclinical model of aggressive leukemia/lymphoma. PLX51107 demonstrates in vivo antitumor effects.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

TCR stimulation by agonistic mAb in vivo administration inhibits mouse T-ALL development. TCR stimulation by agonistic mAb in vivo administration inhibits.

Wild-type mice weight following 6-thio-dG and 6-thioguanine treatment.

The PI3Kβ inhibitor enhances the antitumor activity of T cell–mediated immunotherapy in mice bearing PTEN loss tumors. The PI3Kβ inhibitor enhances the.

TAE-684 effectively inhibits the growth of H3122 in vivo.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

The effect of TGFβ on the post-RT increase of Tregs in tumors.

Constitutive expression of JAK3M511I and HOXA9 leads to development of both AML and T-ALL in vivo. Constitutive expression of JAK3M511I and HOXA9 leads.

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo. MYC expression is correlated with dasatinib sensitivity in cancer.

W. chinensis extract attenuates tumor growth of 103E (a subline of CWR22Rv1) engrafted in the prostate of nude mice. W. chinensis extract attenuates tumor.

Expression of TGFβ ligands in GBM

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

BH3-targeted inhibitors drive specific resistance in human cell lines, which can be overcome with alternating or combining inhibitors. BH3-targeted inhibitors.

ARQ 531 is cytotoxic to CLL cells, decreases NF-κB function, and inhibits migration. ARQ 531 is cytotoxic to CLL cells, decreases NF-κB function, and inhibits.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

STK11/LKB1 genetic alterations are associated with shorter progression-free and overall survival with PD-1 blockade among KRAS-mutant LUAC in the SU2C.

Inhibition of BCR-mediated signaling by ARQ 531.

Inhibition of MCL1 reduces AML in an in vivo murine model.

Kaplan–Meier curves of relapse-free survival of the CAR-T cohort (left) and the HCT cohort (right) of 8 CAR-T patients and 12 HCT patients whose preceding.

Presentation transcript:

ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared with ibrutinib. ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared with ibrutinib. A, C57BL/6 mice engrafted with Eμ-TCL1 leukocytes via tail-vein injection were treated with ARQ 531 for 60 days via daily oral gavage and monitored for survival and drug-induced toxicity. Survival curves were estimated using the Kaplan–Meier method and curve differences among groups were assessed using the log-rank test. B, White blood cell (WBC) counts were measured weekly by microscopic examination. C, A cohort of mice were sacrificed after 2 weeks of treatment, and spleens were weighed to measure disease progression (n = 3 in each group). ANOVA was used to compare spleen weight among groups (*, 0.05 ≥ P > 0.01; **, 0.01 ≥ P ≥ 0.001; ***, P < 0.001). Sean D. Reiff et al. Cancer Discov 2018;8:1300-1315 ©2018 by American Association for Cancer Research